Clinical Trial Update: Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ipatasertib in combination with non-taxane chemotherapy for advanced or metastatic triple-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• ipatasertib (ipatasertib)

Snippet

Sponsor: MedSIR | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED